Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 22

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 22
---
,” or “us”), will be held at 9:00 a.m., Eastern Time, on Wednesday, September 3, 2025, at the offices of US Tiger Securities, Inc. located at 437 Madison Avenue, 27th Floor, New York, New York 10022. You are cordially invited to attend the Meeting for the purpose of considering and, if thought fit, passing with or without amendments, the following resolutions:

| • |     | Proposal 3 — The Charter Approval Proposal  —                                                                                                                                                                                                       
 “RESOLVED, AS A SPECIAL RESOLUTION THAT, in connection with the change of the domicile of Denali pursuant to a transfer by way of continuation of an exempted company out of the Cayman Islands and a domestication into the State of Delaware as a 
 corporation, and the de-registration of Denali in the Cayman Islands (the “Domestication”), the replacement of Denali’s Amended and Restated Memorandum and Articles of Association, as in                                                          
 effect as of the date hereof, with the proposed certificate of incorporation of Denali, in the form attached to this                                                                                                                                |

i

| • |     | Proposal 5 — The Advisory Governance Proposals —                                                                                                                                                        
 “RESOLVED, AS AN ORDINARY RESOLUTION THAT, ON A NON-BINDING ADVISORY BASIS, certain governance provisions contained in the Proposed Charter, being presented in accordance with the requirements of the 
 U.S. Securities and Exchange Commission as seven separate sub-proposals, be and are hereby approved and adopted (collectively, the “Advisory Governance Proposals”), none of which are conditioned on   
 any Condition Precedent Proposals:                                                                                                                                                                      |

| • |     | Advisory Proposal A — to increase the total number of authorized shares of all classes of                                                             
 capital stock to 785,000,000 shares, consisting of 740,000,000 authorized shares of common stock and 45,000,000 authorized shares of preferred stock; |

| • |     | Advisory Proposal B — to provide that subject to the rights of any holders of preferred stock                                                                                                                                                            
 to elect directors, the number of directors that shall constitute the New Semnur Board shall be as determined from time to time exclusively by the New Semnur Board, except that until such time as the Scilex Trigger Event occurs, the stockholders of 
 New Semnur shall be permitted to fix the number of directors;                                                                                                                                                                                            |